

PRESS RELEASE

Gothenburg, Sweden | September 8, 2026

Calmino signs U.S. agreement with Nasdaq-listed Immuron to launch PROIBS®



Calmino group AB has entered into an exclusive distribution agreement with Australian biotechnology company Immuron Limited to launch PROIBS® in the United States. The agreement will bring the IBS product developed in Gothenburg to the world's largest market for digestive health products.

Immuron Limited is listed on both Nasdaq in the United States (NASDAQ: IMRN) and the Australian Securities Exchange (ASX: IMC). The company will be responsible for the marketing and sale of PROIBS® in the U.S. market.

"The United States is a strategically important market for Calmino. Through Immuron, we gain an established partner with experience in the U.S. market and a clear focus on digestive health. For a smaller Swedish life science company, bringing a proprietary product from Gothenburg to the United States represents a major milestone," **Tobias Kisker, CEO and Founder of Calmino group AB**

The agreement builds on the existing collaboration between Calmino and Immuron in Australia, where Immuron launched PROIBS® during its 2026 financial year.

Strong international interest in the agreement

Since Immuron announced the agreement on September 4, the news has received widespread coverage in U.S. and international financial media.

Immuron's share price rose sharply on Nasdaq during the trading session and closed approximately 62 percent higher than on the previous trading day. The stock also traded at an exceptionally high volume. The U.S. digestive and gut health supplement market is estimated to be worth USD 4.16 billion. Immuron intends to target a segment of this market with PROIBS®.

Market leader in Sweden

PROIBS® was developed by Calmino in Gothenburg and launched in Swedish pharmacies in 2010. According to sales data from IQVIA, PROIBS® was the best-selling IBS product in Swedish pharmacies during the full year 2025, measured by both sales value and number of packs sold.

In Europe, PROIBS® is a CE-marked medical device developed to relieve symptoms associated with IBS, including abdominal pain, bloating, diarrhea and constipation. The product is based on the proprietary plant extract AVH200®.

Calmino currently exports its products to 16 countries across Europe, the Middle East and Australia. The agreement with Immuron expands the company's international presence to include the United States.

About Calmino group AB

Calmino group AB is a Swedish life science company founded in 2003 and based at Sahlgrenska Science Park in Gothenburg. The company develops and commercializes science-based products within digestive health.

For more information: www.calmino.com | www.proibs.eu

About Immuron Limited

Immuron Limited is an Australian biotechnology company focused on the development and commercialization of digestive health products. The company is listed on Nasdaq (NASDAQ: IMRN) and the Australian Securities Exchange (ASX: IMC).

For more information: www.immuron.com.au

Media contacts

Tobias Kisker

CEO and Founder, Calmino group AB
tobias.kisker@calmino.com

Fredrik Larsson

Product Manager, Calmino group AB
fredrik.larsson@calmino.com
+46 (0)31 40 72 50